https://i.vimeocdn.com/video/1115432997-6644ee55f947906578d2e904078ef78f23a3d2dfbe64ec65fea36233c8c0847b-d

GEMCOVAC™-19

Gennova’s mRNA vaccine, GEMCOVAC™-19, which is stable at 2-8°C,

has received the Emergency Use Authorization (EUA)

GEMCOVAC™-19

Gennova’s mRNA vaccine, GEMCOVAC™-19, which is stable at 2-8°C,

has received the Emergency Use Authorization (EUA)

1. GEMCOVAC™-19 - SmPC (pdf)Download

2. GEMCOVAC™-19 - Fact Sheet (pdf)Download

3. GEMCOVAC™-19 - Package Insert (pdf)Download

Gennova Biopharmaceuticals Limited

CIN – U24231PN2001PLC016253
T-184, MIDC, Bhosari, Pune – 411 026,
Maharashtra, India.

R&D Address:

BTS – 2 Building, Chrysalis Enclave, Block – 2, Plot -2,
TCG International Biotech Park,
Phase II, MIDC, Hinjawadi, Pune – 411 057,
Maharashtra – India

Manufacturing Address:

Block -1, Plot P1 & P2, ITBT Park, Phase II, MIDC,

Hinjawadi, Pune – 411 057, Maharashtra, India.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Decline Accept